Material Management Information related to Judgment of Investment(에페사프리필드시린지주(GXE4) 한국 품목허가 재신청)

Nov 14, 2024Genexine, Inc.

Material Management Information related to Judgment of Investment(에페사프리필드시린지주(GXE4) 한국 품목허가 신청 자진취하)

Nov 14, 2024Genexine, Inc.

Additional Listing(타법인흡수합병)

Oct 16, 2024KOSDAQ STOCK MKT.

Other Management Information(Voluntary Disclosure)(소규모합병 승인 이사회 결의(주주총회 갈음) 결과보고 )

Aug 29, 2024Genexine, Inc.

[Investment Caution] Issue traded by linked accounts with high market influence

Aug 8, 2024

[Revised]Decision on Merger(소규모합병)

Jul 29, 2024Genexine, Inc.

[Revised]Decision on Merger

Jul 8, 2024Genexine, Inc.

[Revised]Decision on Merger

Jul 1, 2024Genexine, Inc.

Decision on Merger(소규모합병)

Jun 26, 2024Genexine, Inc.

Material Management Information related to Judgment of Investment(IND Approval Determination)(건강한 자원자 코카시안 및 아시아인에서 efepoetin alfa 단회 정맥 투여 후 약동/약력학적 특성, 안전성 및 내약성을 평가하기 위한 GX-E4 1상 임상계획 승인 )

May 29, 2024Genexine, Inc.

[Revised]Lawsuit (Charging More Than Certain Amount)

May 20, 2024Genexine, Inc.

Lawsuit (Charging More Than Certain Amount)

May 7, 2024Genexine, Inc.

Outcomes of Annual Meeting of Shareholders

Mar 28, 2024Genexine, Inc.

Material Management Information related to Judgment of Investment(Application for IND Approval)(건강한 자원자 코카시안 및 아시아인에서 efepoetin alfa 단회 정맥 투여 후 약동/약력학적 특성, 안전성 및 내약성을 평가하기 위한(GX-E4) 1상 임상계획 승인 신청)

Mar 20, 2024Genexine, Inc.

Resolutions for Convocation of General Meeting of Shareholders

Mar 13, 2024Genexine, Inc.

Submission of Audit Report

Mar 12, 2024Genexine, Inc.

30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations)

Feb 7, 2024Genexine, Inc.

[Revised]Material Management Information related to Judgment of Investment(GX-E4(지속형 빈혈 치료제)기술이전 계약체결)

Jan 31, 2024Genexine, Inc.

[Revised]Material Management Information related to Judgment of Investment(에페사프리필드시린지주(GX-E4) 한국 품목허가 신청)

Jan 26, 2024Genexine, Inc.

Material Management Information related to Judgment of Investment(에페사프리필드시린지주(GX-E4) 한국 품목허가 신청)

Jan 25, 2024Genexine, Inc.

[Revised]Submission of Audit Report(2021사업연도)

Jan 9, 2024Genexine, Inc.

[Revised]Submission of Audit Report(2022사업연도)

Jan 9, 2024Genexine, Inc.

Other Market Information(연구개발 우수기업 매출액 특례적용 관련)

Jan 8, 2024KOSDAQ STOCK MKT.

[Revised]Material Management Information related to Judgment of Investment(GX-E4(지속형 빈혈 치료제)기술이전 계약체결)

Dec 28, 2023Genexine, Inc.

Material Management Information related to Judgment of Investment(Study Results)(비투석 신장질환 환자의 GX-E4(빈혈치료제) 제 3상 임상시험 결과)

Dec 22, 2023Genexine, Inc.

Material Management Information related to Judgment of Investment(Study Results)(불응성 또는 재발성 삼중음성유방암 환자를 대상으로 pembrolizumab과 병용한 GX-I7 제1b/2상 임상시험 결과)

Dec 18, 2023Genexine, Inc.

[Revised]Material Management Information related to Judgment of Investment(IND Approval Determination)(GX-E4(빈혈치료제)의 국내 제 3상 임상시험계획(IND) 승인)

Nov 23, 2023Genexine, Inc.

Material Management Information related to Judgment of Investment(IND Approval Determination)(GX-E4(빈혈치료제)의 국내 제 3상 임상시험계획(IND) 승인)

Nov 23, 2023Genexine, Inc.

[Revised]Material Management Information related to Judgment of Investment(GX-170의 국내1상 임상시험계획(IND) 승인)

Nov 1, 2023Genexine, Inc.

Change of CEO

Oct 12, 2023Genexine, Inc.